Key statistics
As of last trade, Oric Pharmaceuticals Inc (4TZ:FRA) traded at 9.00, 46.34% above the 52 week low of 6.15 set on Jun 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.65 |
---|---|
High | 9.00 |
Low | 8.65 |
Bid | 9.05 |
Offer | 9.20 |
Previous close | 8.05 |
Average volume | 100.22 |
---|---|
Shares outstanding | 70.54m |
Free float | 64.10m |
P/E (TTM) | -- |
Market cap | 643.35m USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:02 GMT.
More ▼
- ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
More ▼